Table 1.
Characteristics of IBD patients and healthy controls.
| Ulcerative Colitis (n = 14) |
Crohn’s Disease (n = 23) |
Healthy Control (n = 14) |
|
|---|---|---|---|
| Age (years) | 13.25 ± 2.94 | 13.73 ± 3.10 | 15.21 ± 2.41 |
| Gender (M/F) | 4/10 | 9/14 | 5/9 |
| Weight (Kg) | 21.43 ± 1.51 * | 33.79 ± 3.876 * | 47.9 ± 4.73 |
| Height (cm) | 114 ± 3.088 * | 136.95 ± 5.071 * | 152.8 ± 7.67 |
| Rectal Bleeding | 14 (100%) | 13 (56.5%) | - |
| Diarrhea | 14 (100%) | 19 (82.6%) | |
| Disease Duration (months) | |||
| < 6 months | 50% | 39% | - |
| Paris classification | |||
| Location | left-sided 4 (28.6%) | terminal ileum 8 (34.8%) | - |
| extensive 2 (14,3%) | colon 4 (17.4%) | ||
| pancolitis 8 (57.1%) | ileocolon in 11 (47.8%) | ||
| Behavior | N/A | non-stricturing, non-penetrating 16 (69.6%) | - |
| stricturing 4 (17.4%) | |||
| Penetrating 3 (13.04%) | |||
| Mayo Score | Mild 0 | N/A | - |
| Moderate 5 (35.7%) | |||
| Sever 9 (64.3%) | |||
| Therapy | |||
| Mesalamine | 14 (100%) | 18 (78.3%) | |
| Prednisone | 12 (85.7%) | 23 (100%) | |
| Azathioprine | 12 (85.7%) | 23 (100%) | |
| Sulphasalazine | 0 | 10 (43.5%) | |
N/A - not applicable.